Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Should Medical Professionals Wear Eye Protection to Prevent Radiation Exposure?

Your eyes are two of your body’s most valuable and sensitive organs, yet, when working with radiation, it’s still not standard practice to protect the eyes as well as current technology allows. While attention to eye safety and the use of leaded eyewear are starting to come to the forefront of medical thinking, improvements can…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Your eyes are two of your body’s most valuable and sensitive organs, yet, when working with radiation, it’s still not standard practice to protect the eyes as well as current technology allows.

While attention to eye safety and the use of leaded eyewear are starting to come to the forefront of medical thinking, improvements can still be made to better protect your eyes from lasting damage.

Risks Associated with Radiation Exposure Involving the Eyes

When your eyes are exposed to even low doses of radiation, conditions like vision loss and cataracts can result. As exposure gets higher, so do the consequences – iris damage, conjunctiva, sclera, retinal damage, tumor growth, glaucoma and more can result from inattention to proper protection.

The lens of the eye is one of the most radiosensitive tissues humans have1, and, though medical professionals are developing a thorough understanding of the aforementioned risks, a lack of reliable values for harmful eye doses has persisted.

In fact, though the International Commission of Radiological Protection (ICRP) has accepted a threshold of 0.5 Gy, values ranging well below that threshold could contribute to cataract formation and other injuries2. Furthermore, the ICRP now recommends a dose limit for the lens of the eye of 20mSv in a year averaged over a five-year period, with no single year eclipsing 50 mSv.

Lowering Your Risk with Adequate Protection

Medical professionals and interventional radiologists at risk for radiation exposure should be aware of several factors that can help reduce eye doses, including:

  • Optimal position of the X-ray tube under the patient table
  • Use of ceiling-mounted screens during all procedures, regardless of scope
  • Consistent use of appropriately fitting lead eyewear for protection

That final risk-avoidance strategy is one of the easiest to implement – lead glasses should be worn any time medical professionals are employing lead protection elsewhere on their body, and the use of such eyewear can reduce lens-dose rate by a factor of five to 10 even without the aid of other preventative measures2.

Combining lead eyewear with scatter-shielding screens can be even more effective, reducing dose rate by a factor of five to 252.

Staff doses can be significant, even for staff members not directly involved in the procedure, so making the use of protective eyewear a priority and a best practice should be high atop the list of medical professionals.

AliMed, offers a variety of stylish and protective lead eyewear options from well-known brands like Nike, Oakley, Rudy Project and Costa. All eyewear is designed to help protect your eyes without the imposition of heavy, awkward pairs of glasses, meaning the days of bulky, unattractive solutions to eye protection are over.

All AliMed eyewear is designed with ALARA (As Low As Reasonably Achievable) protocol in mind and meets the recommended 0.75 mm Pb-equivalent protection for front lenses and 0.5 mm Pb-equivalent protection from additional peripheral lenses on some options.

To learn more about AliMed’s protective eyewear offerings, visit Radiation Protection Glasses

RESOURCES:

  1. https://www.uptodate.com/contents/radiation-risk-to-healthcare-workers-from-diagnostic-and-interventional-imaging-procedures
  2. https://www.iaea.org/resources/rpop/health-professionals/radiology/cataract/staff#7

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512